Xolair subcutaneous injection 300mg pen

Xolair subcutaneous injection 300mg pen (YJ code: 2290400G5027, standard: 300mg 2mL 1 kit) is a Novartis Pharma medication containing Omalizumab (genetical recombination). It is used for moderate to severe persistent asthma in patients aged 6 years and older, chronic spontaneous urticaria in those 12 years and older, and chronic rhinosinusitis with nasal polyps in adults.